Protecting discoveries to continue work into the future.

Our scientists have extensive experience with designing and creating nucleic acid compounds for therapeutic applications. Based on our pioneering insights, we have created nucleic acid constructs that act as antagonists of toll-like receptors (TLRs), agonists of TLRs, and gene silencing oligonucleotides (GSOs) or antisense compounds.

We protect our discoveries using a variety of methods, including filing U.S. and foreign patent applications for the proprietary technologies, inventions, and improvements that are important to the development of our business. Through our patent application filings, we have assembled a substantial patent portfolio covering all of our technologies. This patent portfolio currently includes more than 500 patents and patent applications in the United States and other countries throughout the world.

At Idera, we devote a substantial amount of resources to intellectual property protection for:

  • Nucleic acid compounds that function as TLR3, 7, 8, or 9 agonists
  • Nucleic acid compounds that function as TLR7 and TLR9 antagonists
  • Third-generation antisense oligonucleotides
  • Use of our nucleic acid chemistry, nucleic acid compounds, GSOs, or antisense oligonucleotides to treat or prevent a variety of diseases

In addition to seeking patent protection, we rely on trade secrets, know-how, continuous technological innovations, and in-licensing opportunities to develop and maintain our proprietary position.